https://rqbglobal.com/ ..... => ..... https://www.jbbatterychina.com/

Not sure what link you're referring.
Ravenquest if that is what you're reviewing/vetting etc is a waste of time.
It was on the level with it's shareholders up till 12-14 mnths ago. Then all communications suddenly stopped.
Nothing but perpetual radio silence.

Website link above goes to Chinese battery company?!?!

This is a ghost entity. I tapped out a year ago after losing 60% of my holdings.
At least it wasn't 100%.
Amazing to see it still trading when the I read so much press about it's legal issues and shady activity.
Take it for what it's worth but be warned.

What's going on here did we miss some news ?

Nothing but lies from this company it's a complete scam.

RAVENQUEST GROWS THEIR FIRST PLANT!

This company is dog shit with hardly any money and they acquire digigro what the heck so stupid.Nothing but a scam.

RavenQuest Announces Change to Board of Directors
Email Print Friendly Share
November 29, 2019 17:34 ET | Source: RavenQuest BioMed Inc.
VANCOUVER, British Columbia, Nov. 29, 2019 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) (the “Company” or “RavenQuest”), today announced that Cassidy McCord has been appointed director of the Company. Ms. McCord’s bio can be found below. RavenQuest further announces the resignation from the board of Mark Ahrens-Townsend.

“As RavenQuest evolves toward profitability, the composition of our board has taken shape to reflect our plans for 2020 and beyond," said George Robinson, RavenQuest CEO. "To fully realize our potential moving forward, I’m confident recent changes at the board level will provide impactful leadership and perspective as we transition from a start-up into an operating company.” Robinson continued.

Cassidy McCord

Ms. McCord has a medicinal cannabis background, focusing on company reorganization and patient processing. She has also held the position of director for a publicly traded cannabis company and also holds a business administration diploma from Vancouver Island University

For more information, access RavenQuest’s investor presentation, fact sheet and videos here.

Follow RavenQuest:
Twitter
Instagram
Facebook
LinkedIn

About RavenQuest BioMed Inc.

RavenQuest is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development. RavenQuest is a licensed producer with facilities located in Markham, Ontario and Edmonton, Alberta.

RavenQuest maintains a research partnership with McGill University focused upon cultivar (strain) recognition, plant stabilization and yield maximization of the cannabis plant. The Company also focuses on partnerships with Indigenous communities.

On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.

“George Robinson”
Chief Executive Officer

For further information, please contact:
Mathieu McDonald, Corporate Communications
1-877-282-1586

POS stock

I called in 2018 and asked very specific questions about Roto Grows technology. They told me that Orbital Gardens had been around for 40 yrs. Then I asked, if that is true how did they get a patent? Then I stated there can be separate claims for patents are you certain you have not violated any of their claims. Then he said, they had met with them years ago and everything is alright. Talk to George, of course he wasn't there and I could never get in touch with him. These people ate idiots if they thought they could get away with that. Patent violations cases are long, drawn out & very expensive

WOW! I actually called them out on this back in 2017 and their IR guy said they had the rights ..what BS that IR guy was selling!

RotoGro Files Patent Statement of Claim$RGI #ASX #agtech #ausbiz #RotoGro #RotatingGarden #Cannabis #UrbanVerticalFarming

Read the full announcement here:https://t.co/KYZq4fGdnN pic.twitter.com/bnjKiWQoz9

— RotoGro (@rotogro) November 3, 2019

site tour, pretty cool:

Wow glad I didn't buy into the pumping on this. Total disaster. Especially their IR guy, he's clueless and a pumper.

All this news and the pos sinks

Big news this Australia deal announcement. Ravenquest making high-potential moves. I did like the CEO's energy and upbeat demeanor during that Midas Letter interview. Nothing sluggish about him.

News out - RavenQuest Receives Health Canada Permit for Export to Australia
Email Print Friendly Share
October 08, 2019 06:00 ET | Source: RavenQuest BioMed Inc.
VANCOUVER, British Columbia, Oct. 08, 2019 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) (the “Company” or “RavenQuest”), one of Canada’s most innovative cannabis producers, announces that it has received a permit from Health Canada to allow the Company to export cannabis to Australia.

The permit allows for the export of dried cannabis flower from the Company to Medcan Australia (“Medcan”), a federally licensed Australian medical cannabis provider. Shipments from RavenQuest to Medcan are targeted to begin in mid-October.

Founded in 2016, Medcan has a singular vision to provide Australian patients with a high-quality, fair-priced product. With a vertically integrated model, Medcan is licenced under the Office Drug Control to cultivate, produce, manufacture, export and import high quality medicinal cannabis products for both clinical trials and individual patient access throughout Australia.

RavenQuest CEO, George Robinson, stated “the Australian medical cannabis model is well developed and mirrors Canada’s early evolution in many respects. With a population of over 24 million residents, this is a significant market with real growth potential. The Special Access Scheme in Australia has been updated recently, making it easier to access medical cannabis. Of the 14,420 applications approved, 13,217, or 92%, occurred within the last 12 months, and 2,893, or 20%, in August 2019 alone. It’s clear to us that the Australian medical cannabis market is growing very rapidly and we can now participate in this growth through our export permit with Health Canada.”

Medcan CEO, Craig Cochran, commented “we are very excited to begin receiving cannabis from Canada’s RavenQuest. After a comprehensive facility tour through RavenQuest’s ultra-modern, laboratory-grade cultivation facilities, we are confident their product easily meets our high cleanliness and safety standards. We also had in depth discussions with RavenQuest’s plant science leader, Dr. Simerjeet Kaur and are very comfortable with the RavenQuest team’s ability to continue our commitment to provide the safest and highest quality cannabis to our patients.”

For more information, access RavenQuest’s investor presentation, fact sheet and videos here.

Follow RavenQuest:
Twitter
Instagram
Facebook
LinkedIn

About RavenQuest BioMed Inc.

RavenQuest is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development. RavenQuest is a licensed producer with facilities located in Markham, Ontario and Edmonton, Alberta.

RavenQuest maintains a research partnership with McGill University focused upon cultivar (strain) recognition, plant stabilization and yield maximization of the cannabis plant. The Company focuses on partnerships with Indigenous communities.

On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.

“George Robinson”
Chief Executive Officer

For further information, please contact:
Mathieu McDonald, Corporate Communications
1-877-282-1586

Promising interview with Midas Letter. Am now invested and will hold long and strong.

https://midasletter.com/2019/10/ravenquest-biomed-inc-cnsxrqb-industry-leading-grow-technology-formalizing-european-operations/

Ravenclaw negative 50 points.

RVVQF Daily Chart

RavenQuest Partner McGill University Secures Cannabis License
Email Print Friendly Share
September 26, 2019 06:00 ET | Source: RavenQuest BioMed Inc.
VANCOUVER, British Columbia, Sept. 26, 2019 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) (the “Company” or “RavenQuest”), one of Canada’s most innovative cannabis producers, is pleased to announce that its research partner, McGill University, has received a license from Health Canada which allows for the possession and production of cannabis for research purposes.

The license allows RavenQuest and McGill to continue important research around the cannabis plant. The research continues to focus on cultivar recognition, plant stabilization, yield maximization and disease resistance of the cannabis plant.

RavenQuest CEO, George Robinson, commented that “throughout our partnership with McGill, research has thus far uncovered several key beneficial microbes which have shown significant potential to improve yield and disease resistance. The Health Canada license will allow RavenQuest and McGill to confirm our findings by applying the microbes directly to the cannabis plant.”

“RavenQuest’s foundation is grounded in science and innovation. As a company, we have always maintained that large scale Cannabis producers need to develop non-GMO methods to produce genetically consistent, disease resistant and biologically stable plant material that will meet pharmaceutical standards for clinicians to conduct medical research trials. With the granting of this license, the research we are conducting with our partners at McGill moves us even closer toward that end,” Robinson continued.

For more information, access RavenQuest’s investor presentation, fact sheet and videos here.

Follow RavenQuest:

Twitter:
https://twitter.com/RQBGlobal

Instagram:
https://www.instagram.com/ravenquestbm/

Facebook:
https://www.facebook.com/RavenQuest-BioMed-2355335751374131/?view_public_for=2355335751374131

LinkedIn:
https://www.linkedin.com/company/ravenquest-biomed

About RavenQuest BioMed Inc.

RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development. RavenQuest is a licensed producer with facilities located in Markham, Ontario and Edmonton, Alberta.

RavenQuest maintains a research partnership with McGill University focused upon cultivar (strain) recognition, plant stabilization and yield maximization of the cannabis plant. The Company focuses on partnerships with Indigenous communities.

On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.

It will take years

can we trust their projections? how long is it going to take for them to scale this technology up?

Complete scam at its finest

Pos stock been holding since .74

Actually, it went from $1.04 to $.29, but just as every Stock Prospectus disclaimer reads, "Past performances do not reflect. or guarantee future performances".

Future Earnings are everything, especially in penny stock land.

Good luck to you.

This stock went from 74 cents to 32 cents and this is a treasure ?

One man’s trash is another man’s treasure.

Holding for earnings #’s

Garbage and nothing more

Good expectations, however I am hoping for more

“State the designation and number or principal amount of securities and the eligible institutional investor’s securityholding percentage in the class of securities at the end of the month for which the report is made.
As at the end of June 2019, MM Asset, on behalf of MMCAP, exercised control and direction over:
(i) 4,000,000 Shares
(ii) 10% unsecured convertible debentures in the aggregate principal amount of $12,500,000, entitling the holder to acquire 8,620,690 Shares at a conversion price of $1.45 per Share until March 2, 2020;
(iii) 4,603,500 common share purchase warrants (the “March Warrants”) (each March Warrant entitles the holder to purchase an additional Share at the price of $1.50 per Share until March 22, 2020);
(iv) 2,857,143 common share purchase warrants (the “July Warrants”) (each July Warrant entitles the holder to purchase an additional Share at the price of $0.90 per Share until July 13, 2021),
2
(v) 4,000,000 June Warrants; and
(vi) 3,000,000 Shares pursuant to securities lending arrangements described in Item 3.6 below,
representing approximately 19.10% of the Outstanding Shares, calculated on a partially diluted basis.”

RavenQuest just added with the rebalancing of this ETF


INVESTMENT OBJECTIVE
The Horizons Emerging Marijuana Growers Index ETF (“HMJR”) seeks to replicate, to the extent possible, the performance of the Emerging Marijuana Growers Index (the “Index”), net of expenses. The Index is designed to provide exposure to the performance of a basket of primarily North American publicly-listed small-capitalization companies primarily involved in the cultivation, production and/or distribution of marijuana

Some financials as reported in CEDAR:


RESULTS OF OPERATIONS
Six months ended April 30, 2019 and 2018
For the six months ended April 30, 2019, the Company’s business operated primarily through two operating segments – consulting business, and cultivation and sale of medical cannabis. The Company reports activities not directly attributable to an operating segment under corporate. These operating segments are monitored by the Company’s chief operating decision makers, and strategic decisions are made on the basis of segment operating results.
Revenue Gross profit Net loss before
income tax
$ 634,775 $ $ 693,386 $
$ (407,773) $
318,495 $ (59,371) $
(2,198,287) $
Consulting Medical cannabis
Corporate
- $
- $
(3,793,251) $
Total 953,270
634,015
(6,399,311)
We incurred a net and comprehensive loss of $6,399,311 for the period ended April 30, 2019 (2018 - $4,456,586). The $953,270 in revenue (2018 - $611,395) was as a result of the operations purchased as part of the acquisition made in Q4 2017 and Q2 2018.
During the six months ended April 30, 2019, the Company sold 5,765 plants (2018 - Nil) resulting in revenue of $172,950 (2018 - $Nil).
Cost of Sales
Plants that are in pre-harvest are considered biological assets and are capitalized on the balance sheet at fair market value less cost to sell at their point of harvest. Fair market value estimates are based on the Company’s selling list prices for specific cannabis plant strains. Costs to sell include post-harvest, trimming, fulfilment, testing and shipping costs. The Company capitalizes all the direct and indirect costs as incurred related to the biological transformation of the biological assets between the point of initial recognition and the point of harvest including labour related costs, grow consumables, materials, utilities, facilities costs, and quality and testing costs. As they continue to grow through the pre-harvest stages, a corresponding non-cash unrealized gain is recognized in income, reflecting the changes in fair value of the biological assets. At harvest, the biological assets are transferred to inventory at their fair value, which becomes the deemed cost for inventory. Inventory is later expensed to cost of sales when sold.
The cost of sales of ($58,611) (2018 - $397,001) during the period ended April 30, 2019 was comprised of inventory production costs expensed of $76,149 offset by reversals of previously recorded cost of $134,760.
During the period ended April 30, 2019, the Company recorded cost of sales including realized portion of change on inventory sold of $140,305 (2018 - $Nil).
During the period ended April 30, 2019, the Company recorded unrealized loss on changes in the fair value of biological assets of $237,561 (2018 - $Nil).
Some of the items comprising the loss for the six months ended April 30, 2019 were:
? Advertising and promotion of $197,863 (2018 - $544,794) decreased primarily as a result of decreased activities in the current period to raise awareness regarding the Company’s activities.
? Depreciation and amortization of $1,251,872 (2018 - $5,205) increased primarily as a result of an increase in additions to plant and equipment and intangible assets subsequent to the acquisition made in Q4 2017 and Q2 2018.
? Filing fees of $23,128 (2018 - $33,721) decreased due to decreased share activities during the current period.
? Interest and accretion of $1,545,369 (2018 - $465,472) increased primarily due to interest accrued on the convertible debentures and loans payable during the current period.
? Management and consulting fees of $372,800 (2018 - $1,491,295) decreased primarily due to a decrease in consulting fees during the current period.
? Office expenses of $556,979 (2018 - $164,910) increased as a result of increased expenses required to run the Company acquisitions made in Q4 2017 and Q2 2018.
? Rent of $457,867 (2018 - $299,401) increased due to rentals and leases assumed during the acquisitions made in Q4 2017 and Q2 2018.
? Share-based compensation of $1,080,089 (2018 - $1,363,286) decreased as a result of stock options granted during the period.
? Travel of $141,532 (2018 - $119,433) increased primarily as a result of more trips taken during the current period relating to new operations.
8

? Transfer agent fees of $12,123 (2018 - $17,304) decreased due to decreased share activities during the current period.
? Wages of $932,584 (2018 - $379,764) increased due to new operations in the current period.
Three months ended April 30, 2019 and 2018
For the period ended April 30, 2019, the Company’s business operated primarily through two operating segments – consulting business, and cultivation and sale of medical cannabis. The Company reports activities not directly attributable to an operating segment under corporate. These operating segments are monitored by the Company’s chief operating decision makers, and strategic decisions are made on the basis of segment operating results.
Consulting Medical cannabis
Corporate
- $
- $ (1,611,033) $
Total 653,240
(131,187) (3,797,158)
9
Revenue Gross profit Net loss before
income tax
$ 436,745 $ $ 413,064 $
$ (159,150) $
216,495 $ (544,251) $
(2,026,975) $
We incurred a net and comprehensive loss of $3,797,158 for the period ended April 30, 2019 (2018 - $3,436,044). The $653,240 in revenue (2018 - $614,360) was as a result of the operations purchased as part of the acquisition made in Q4 2017 and Q2 2018.
During the period ended April 30, 2019, the Company sold 2,365 plants (2018 - Nil) resulting in revenue of $70,950 (2018 - $Nil).
Cost of Sales
The cost of sales of $23,681 (2018 - $85,190) during the period ended April 30, 2019 was comprised of inventory production costs.
During the period ended April 30, 2019, the Company recorded cost of sales including realized portion of change on inventory sold of $140,305 (2018 - $Nil).
During the period ended April 30, 2019, the Company recorded unrealized loss on changes in the fair value of biological assets of $620,441 (2018 - $Nil).
Some of the items comprising the loss for the three months ended April 30, 2019 were:
? Advertising and promotion of $80,579 (2018 - $532,147) decreased primarily as a result of decreased activities in the current period to raise awareness regarding the Company’s activities.
? Depreciation and amortization of $480,940 (2018 - $3,958) increased primarily as a result of an increase in additions to plant and equipment and intangible assets subsequent to the acquisition made in Q4 2017 and Q2 2018.
? Filing fees of $17,782 (2018 - $31,028) decreased due to decreased share activities during the current period.
? Interest and accretion of $768,612 (2018 - $459,413) increased primarily due to interest accrued on the convertible debentures and loans payable during the current period.

? Management and consulting fees of $187,800 (2018 - $1,384,920) decreased primarily due to a decrease in consulting fees during the current period.
? Office expenses of $327,762 (2018 - $114,807) increased as a result of increased expenses required to run the Company subsequent to the acquisitions made in Q4 2017 and Q2 2018.
? Rent of $195,633 (2018 - $164,361) increased due to rentals and leases assumed during the acquisitions made in Q4 2017 and Q2 2018.
? Research and development $80,000 (2018 - $40,000) increased due to the timing of expenses recorded by the Company in the current period.
? Share-based compensation of $183,940 (2018 - $661,021) decreased as a result of stock options granted during the period.
? Travel of $72,209 (2018 - $68,204) increased primarily as a result of more trips taken during the current period relating to new operations.
? Transfer agent fees of $3,113 (2018 - $15,176) decreased due to decreased share activities during the current period.
? Wages of $443,548 (2018 - $227,804) increased due to new operations in the current period. LIQUIDITY AND CAPITAL RESOURCES
During the period from November 1, 2018 to June 28, 2019, the Company:
i) issued 1,014,000 shares pursuant to the exercise of options for proceeds of $659,100.
ii) completed a non-brokered private placement of units. In connection with completion of the non-brokered private placement, the Company issued 3,523,832 units at a price of $0.60 per unit for aggregate gross proceeds of $2,114,299.
Each unit consists of one common share of the Company, and one half of one share purchase warrant. Each warrant is exercisable to acquire an additional common share of the Company at a price of $0.08 per share for a period of 24 months. The Company also paid a finder’s fee to qualified finders in respect to the financing.
The Company also paid finders’ fees of $52,014 and issued 82,730 finder’s warrants (valued at $32,700). Each warrant entitles the holder to acquire a common share of the Company at a price per common share of $0.80 for a period of 24 months from the date of issuance.
iii) completed a non-brokered private placement of units. In connection with completion of the non-brokered private placement, the Company issued 166,000 units at a price of $0.60 per unit for aggregate gross proceeds of $99,600.
10
As of April 30, 2019, the Company had a cash position of $1,303,773, compared to $362,810 as at October 31, 2018, representing an increase of $940,963. As of April 30, 2019, the Company had a working capital deficiency of $3,072,462 compared to a working capital of $280,728 as at October 31, 2018.
Inventory at April 30, 2019 increased to $138,160 (October 31, 2018 - $Nil) and biological assets increased to $168,296 (October 31, 2018 - $78,244).

——————————
They sold over 5,000 plants with only revenue of approximately $172,000. I believe that maybe due to having prepaid upfront by Wyland group of $2,000,000.00

Why RavenQuest will succeed:

“Our Orbital Gardens can produce far greater quantities of cannabis on a per-square-foot basis than virtually anyone else in the space, and at greater economic efficiencies due to the substantial savings on input costs of the automated system – a system which requires only five grow-room visits per cycle. All of these benefits contribute to profitability while producing some of the most consistent, repeatable and high-quality cannabis anywhere.

We are delighted to be working alongside such an esteemed group with global reach, who also see the tremendous value in RavenQuest, a company that thoroughly understands the science behind growing the cannabis plant properly and at scale.

The first facility is expected to be constructed in Portugal, and the final stages of site selection are ongoing as we write this new release. We anticipate finalizing our agreement by summer 2019 and moving toward breaking ground shortly thereafter. “
———————
Innovation is what differentiates companies, and when that innovation increases production as well as lowers production costs while improving quality, that will be key as to who succeeds and who does not.

AJMO and worth what you paid for it.

Back YahooFINANCE
RavenQuest Provides Corporate Update
GlobeNewswireJune 26, 2019, 6:00 AM EDT
VANCOUVER, British Columbia, June 26, 2019 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) is pleased to provide the following full update on all aspects of the Company’s production, distribution and expansion plans for 2019 and beyond.

RavenQuest is gearing up for rapid growth in Canada as well as in Europe. Canadian production will accelerate to full capacity by summer 2019 and our European expansion is swiftly taking shape. We anticipate profitable operations in the near term, driven by our focused approach outlined herein.

Canadian Production

SCROLL TO CONTINUE WITH CONTENTAd
Make $1,000 in Your First Month With Lyft
Both of our two ultra-modern grow facilities are built and producing cannabis now. RavenQuest boasts a full license to sell cannabis and two completed and licensed cannabis facilities located in Markham, Ontario and Edmonton, Alberta.

With an eye on prudence, Edmonton production began cautiously to ensure the success of our disruptive Orbital Garden technology. The extensive science behind Orbital Gardening results in a unique cannabis plant, one which expresses as a much more efficient plant with very little wasted leaf (fan leaf) and instead produces almost entirely large buds (image shown below). We are very excited with the results, and as we near completion of the first harvest, we are now comfortable with our processes and are in the midst of rapidly ramping production. The shorter 8-week grow cycle of the Orbital Gardens (compared to 12-14 week cycles for flat table growing) further adds to annual yield. We expect the Edmonton facility to reach full capacity by this summer (2019), placing RavenQuest’s Canadian production run-rate at about 11,000 kg per annum.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/8afc2871-793c-4a19-bdc0-7cb7c1492944
https://www.globenewswire.com/NewsRoom/AttachmentNg/31bdfb14-f980-484f-82f7-0dca7999993f
https://www.globenewswire.com/NewsRoom/AttachmentNg/ff0a5167-f99e-4083-b662-56e63c4d27a3

Markham production is ramping up nicely with the addition of Dr. Simerjeet Kaur, PhD (McGill) demonstrating her value as a plant science leader. RavenQuest plans to convert the Markham facility to Orbital Gardens in mid-2019.

From a production standpoint, we see 2019 as an inflection year for our Company as we accelerate from nominal production in 2018 to an expected run-rate of approximately 11,000 kg per year by mid-summer 2019.

Canadian Sales & Distribution

RavenQuest has a business-to-business supply agreement in place for up to 8,000 kg in 2019.

In addition, RavenQuest has signed an MOU (Memorandum of Understanding) with the province of British Columbia to supply approximately 2,000 kg. We are currently engaged with several other provinces with a view toward diversifying our geographic footprint with the potential for supply agreements with additional provinces in the near future.

With our business-to-business supply agreement and potential sales to British Columbia, our Company has pre-sold the bulk of our production for 2019, and are working on similar arrangements in both the B2B and recreational markets for 2020 as well.

The cannabis market remains in short supply and we expect this dynamic to persist well into 2020, especially for high quality, indoor grown dried flower or full plant extracts, which is an area of focus for our Company.

We see the evidence in other cannabis markets that dried flower and vaporizers are still a preferred delivery method even after the introduction of edibles and concentrates. Dried flower and vaporizers still account for upwards of 65% of the marketplace in many fully legal edibles environments. We anticipate adding an elegant and disposable vaporized product to our portfolio leading into Cannabis 2.0 (legalization of edibles). We believe strongly in the concept of the “entourage effect”, or the “full plant experience” for cannabis enthusiasts and our vaporizers will carry this same emphasis on the “full plant extract”. We think in terms of the “Fresh Squeezed Orange Juice” of cannabis, rather than the “Tang” or “Kool-Aid” approach, which tends to focus upon fractional distillates.

It has been evidenced that those companies with a more simplified approach are having the greatest on-the-ground as well as financial success, and we intend to walk this path as well. We have a select number of high-quality SKUs, a conservative branding budget and a laser focus upon delivering quality product in simple, biodegradable packaging that emphasizes moisture and quality. We believe this is the pathway to success and this has been demonstrated by a select peer group thus far in the broader market. In our view, quality and consistency will outpace volume and advertising as we address our consumer base. We anticipate profitable operations near term as a result of this focused, sensible approach to the business of cannabis.

European Expansion

RavenQuest sees tremendous opportunity in Europe, and has announced a Heads of Agreement toward a Joint Venture with Norway’s Biocare, which intends to produce upwards of 35,000 kg per year, split on a 50/50 basis between RavenQuest and Biocare.

Of note is that funding of the expansion is anticipated to come from Biocare, while RavenQuest brings its technology, facility design and expertise.

Europe has a population of over 700 million and a growing acceptance of cannabis as both a medicine and a recreational product. RavenQuest has aggressive expansion plans in Europe with our partner, Biocare.

Led by Gerhardt Ludvigsen and his team from Petronor/Hemla, our Norwegian partners completed an extensive due diligence process, which included some of the largest players in the cannabis space. Ultimately, they decided to partner with RavenQuest because our organization has placed the foundation of our business into science and innovation. Our Orbital Gardens can produce far greater quantities of cannabis on a per-square-foot basis than virtually anyone else in the space, and at greater economic efficiencies due to the substantial savings on input costs of the automated system – a system which requires only five grow-room visits per cycle. All of these benefits contribute to profitability while producing some of the most consistent, repeatable and high-quality cannabis anywhere.

We are delighted to be working alongside such an esteemed group with global reach, who also see the tremendous value in RavenQuest, a company that thoroughly understands the science behind growing the cannabis plant properly and at scale.

The first facility is expected to be constructed in Portugal, and the final stages of site selection are ongoing as we write this new release. We anticipate finalizing our agreement by summer 2019 and moving toward breaking ground shortly thereafter.

Operational Summary

Between our Canadian ramp-up and European expansion, its an exciting time for us at RavenQuest. We’re now producing cannabis at scale, accelerating production rapidly and have begun selling cannabis and realizing revenues.

Now that our Orbital Garden technology has been proven inside our Edmonton facility, our relationship with Biocare is expected allow us to take production to scale in Europe.

For more information, access RavenQuest’s investor presentation, fact sheet and videos here.

Follow RavenQuest on Twitter @RQBGlobal.

About RavenQuest BioMed Inc.

RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development. RavenQuest is a licensed producer with facilities located in Markham, Ontario and Edmonton, Alberta.

RavenQuest maintains a research partnership with McGill University focused upon cultivar (strain) recognition, plant stabilization and yield maximization of the cannabis plant. The Company focuses on partnerships with Indigenous communities.

On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.

“George Robinson”
Chief Executive Officer

For further information, please contact:
Mathieu McDonald, Corporate Communications –-877-282-1586

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statements

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including production at our Edmonton and Markham facilities, the supply of cannabis to the Province or British Columbia pursuant to the MOU, the state of the cannabis market, our expansion into Europe, statements with respect to the execution of a definitive JV agreement between RavenQuest and Cannabis BioCare, the construction of cannabis production facilities in certain geographic regions and the production capacity of those facilities. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.


Start the conversation


What to Read Next

Haven't checked in here for a while. I see share price is in downtrend. And how come no current financials? Last Q was terrible. When will real revs kick in?

Is RavenQuest a diamond in the ruff,...some people think so.

Mr. Ludvigsen stated, “Our organization has quietly and patiently conducted research as a pre-cursor to entry into the global cannabis marketplace. Our due diligence process has been exhaustive and has involved conversations with several Canadian cannabis companies including five companies with market capitalizations in the billions of dollars. Ultimately, we chose to partner with one of the most scientific, innovative and fundamentally sound cannabis projects worldwide, namely RavenQuest BioMed.”
“

RavenQuest BioMed Expands Into Europe
GlobeNewswireMay 22, 2019, 6:00 AM EDT
VANCOUVER, British Columbia, May 22, 2019 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT1) (the “Company” or “RavenQuest”) is pleased to announce that it has signed a Heads of Agreement (the “HoA”) with Norway's Cannabis Biocare A/S (“Cannabis Biocare”) to enter into a joint venture (“JV”) to construct cannabis production facilities using RavenQuest's Orbital Garden grow technology in certain geographic regions. It is anticipated that production facilities will be constructed within twenty-four months, with the capacity to produce up to 35,000 kilograms of cannabis annually. RavenQuest will own a fifty-percent equity interest in the JV.

According to the HoA, RavenQuest will grant the JV use of its Orbital Garden grow technology, intellectual property and developed microbes.

Cannabis Biocare will provide full funding for facility build-outs and cannabis technologies including orbital gardens and startup expenses for all facilities within the regions

European expansion for RavenQuest[/

RavenQuest BioMed Expands Into Europe
GlobeNewswireMay 22, 2019, 6:00 AM EDT
VANCOUVER, British Columbia, May 22, 2019 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT1) (the “Company” or “RavenQuest”) is pleased to announce that it has signed a Heads of Agreement (the “HoA”) with Norway's Cannabis Biocare A/S (“Cannabis Biocare”) to enter into a joint venture (“JV”) to construct cannabis production facilities using RavenQuest's Orbital Garden grow technology in certain geographic regions. It is anticipated that production facilities will be constructed within twenty-four months, with the capacity to produce up to 35,000 kilograms of cannabis annually. RavenQuest will own a fifty-percent equity interest in the JV.

According to the HoA, RavenQuest will grant the JV use of its Orbital Garden grow technology, intellectual property and developed microbes.

Cannabis Biocare will provide full funding for facility build-outs and cannabis technologies including orbital gardens and startup expenses for all facilities within the regions

”Both our Edmonton and Markham facilities are built to European Good Manufacturing Practices (EU GMP) specification, and we are working vigorously toward that certification for both facilities”

Looks like they will be seeking to sell cannabis anywhere in the world it is legal. I believe one day their product will be highly sought after because of all the replication controls used in their production in using Orbital Gardens, and their scientific affiliations geared at control of product strains and associated academic research.

Nice volume yesterday may attract new investors today. They also have a good and unique plan for going forward. We shall see.

No reason for RQ SP not to start appreciating. They have sold their total production inventory for 2019 at a very good rate. They should have other production facilities come online next year and considering the shortages nationwide of inventory there is a good chance they will sell their complete production inventory next year at an increased output. Everything is looking very good for RavenQuest. Next objective seems to be the European market.

RavenQuest Awarded its First Cannabis Sales License from Health Canada

GlobeNewswire•May 3, 2019
VANCOUVER, British Columbia, May 03, 2019 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) (the “Company” or “RavenQuest”) a federally-licensed producer of cannabis, is pleased to announce it has secured a Health Canada sales license at the Company’s Markham facility, also known as “Bloomera Inc.” The license allows RavenQuest to commence sales of both medical and recreational cannabis nationwide.

Importantly, the license allows RavenQuest to route production from both its Markham and Edmonton facilities through Markham, effectively allowing all RavenQuest production to be sold through the Markham sales license.

“This is a major milestone for our company and is a testament to the hard work and dedication of our team,” stated George Robinson, RavenQuest CEO. “It marks the beginning of our recreational cannabis presence as we roll out our branded product line, Lore Cannabis™. RavenQuest’s brand will stand on the solid foundation of science and innovation. Our focus on the plant allows for consistent, repeatable and high-quality cannabis from our disruptive Orbital Gardens.”

“We’ve been preparing for this day and have maintained an active dialogue with provincial wholesalers. This license opens the door for the next logical step of finalizing supply agreements with provincial wholesalers as well as the pursuit of European sales. Both our Edmonton and Markham facilities are built to European Good Manufacturing Practices (EU GMP) specification, and we are working vigorously toward that certification for both facilities. It’s an exciting time at RavenQuest as our company enters a new era – reaping the rewards of the research, investment and hard work of the past 18 months as we built the foundation for what is now a fully licensed and operational cannabis company,” Robinson continued.

For more information, access RavenQuest’s investor presentation, fact sheet and videos here.

Follow RavenQuest on Twitter @RQBGlobal

Someone believes in RQ:

April 17, 2019 – Toronto, ON – Cannabis Growth Opportunity Corporation (“CGOC”, or the “Company”) (CSE: CGOC), a cannabis-focused investment corporation with both public and private cannabis holdings, announces the company’s updated net asset value per common share (“NAV”) of $3.54 at the close of business on April 15, 2019. This represents growth of 53% since our Initial Public Offering on January 26, 2018, or 27.8% year to date.



CGOC is now approximately 98% percent invested in companies operating in Canada, the U.S., Jamaica and Israel. CGOC’s top ten public investments as of April 15, 2019 (in alphabetical order) are: Indus Holding Company (not yet public), C21 Investments Corp. (CSE : CXXI), Cannex Capital Holdings Inc. (CSE : CNNX), GR Companies Inc (note yet public), ICC International Cannabis Corporation (CSE: WRLD.U), Indiva Limited (TSX-V: NDVA), LPF Investment Corp. (not yet public), Ravenquest BioMed Inc. (CSE: RQB), Vireo Health Inc. (CSE: VREO) and VIVO Cannabis (TSX-V : VIVO).

If RQ delivers on their projection of 10 kilos production and sales for 2019 we could see YOY growth of 3300% That could add significantly to the SP.

Ravenquest Provides Update on Recent License and Production Capacity Expansion

GlobeNewswire•April 10, 2019
VANCOUVER, British Columbia, April 10, 2019 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) (the “Company” or “RavenQuest”) a federally licensed producer of cannabis, is pleased to provide an update following receipt of its cultivation license at its Edmonton facility and the capacity expansion that comes with it.

Licensing of the Edmonton facility represents an inflection point for the Company, increasing its licensed annual cannabis production capacity to 11,000 kg—a 275% increase.

RavenQuest currently has a supply agreement with Wayland Group, whereby RavenQuest has agreed to supply them with up to 8,000 kg of cannabis in 2019. RavenQuest has also entered a memorandum of understanding with the British Columbia Liquor Distribution Branch (“BCLDB”) and expects to enter into an agreement in to sell the remainder of its cannabis production to them in 2019.

With respect to ramping up production at the newly licensed Edmonton facility, RavenQuest CEO, George Robinson stated “we have an experienced team in place at both Edmonton and Markham facilities to ensure starting material is expedited safely from the Markham facility to the Edmonton facility. Our experience in cannabis consulting, together with the seasoned plant expertise of Dr. Simerjeet Kaur and her team will enable us to bring production online in Edmonton properly and at a rapid pace”.

“With the Edmonton facility online, RavenQuest is on track to fulfill its supply agreement with the Wayland Group and expects to be in a position to supply the BCLDB with cannabis once a definitive supply agreement is reached” Robinson continued.

In addition to an increase in cannabis revenue for 2019, RavenQuest also anticipates a record year for its Services Division, with several new clients signing contracts including, notably, a one year agreement with Bonify valued at $1.5 million.

Once legalized, RavenQuest intends to deliver on its broader growth strategy to provide value-added products across a wide spectrum of delivery options including vaporization, edibles and beverages. “Our plans include a diversified product offering of unique experiences for cannabis consumers. These products will differ substantially from the fractional distillates planned by our competitors. Instead, we will place the emphasis on the full plant extract, with the myriad flavours and profiles that come with passing through the full plant experience to value added products” stated Robinson.

“As we move past the licensing phase,” stated Robinson, “2019 promises to be an unprecedented year for RavenQuest and our stakeholders. We are excited to take the Company from the buildout phase to the revenue and profitability phase, and continuing to accelerate our growth trajectory. There is much to look forward to for RavenQuest BioMed in 2019.”

For more information, view RavenQuest’s updated website at www.rqbglobal.com.

The BCLDB is responsible for regulating private retail cannabis licensing and the distribution of cannabis to retail stores in British Columbia's legal adult-use recreational cannabis marketplace. The MOU does not represent a binding purchase agreement, and any distribution of cannabis products to the BCLDB is subject to the negotiation of such an agreement on the terms specified by the BCLDB. The Company will provide additional information regarding the BCLDB supply and distribution process as it becomes available.

Follow RavenQuest on Twitter @RQBGlobal

About RavenQuest BioMed Inc.

RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development. RavenQuest is a licensed producer with facilities located in Markham, Ontario and Edmonton, Alberta.

RavenQuest maintains a research partnership with McGill University focused upon cultivar (strain) recognition, plant stabilization and yield maximization of the cannabis plant. The Company focuses on partnerships with Indigenous communities.

On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.

"George Robinson"
Chief Executive Officer

For further information, please contact: Mathi

Up 13% to.54

RavenQuest Secures Health Canada Cultivation License at Edmonton Facility

GlobeNewswire•April 5, 2019
VANCOUVER, British Columbia, April 05, 2019 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) (the “Company” or “RavenQuest”) a federally-licensed producer of cannabis, is pleased to announce it has secured a Health Canada License to Cultivate at the Company’s flagship Edmonton facility. The license allows RavenQuest to begin cannabis production inside the revolutionary Orbital Garden 2.0 grow technology at its ultra-modern Edmonton production facility. The Edmonton facility increases RavenQuest’s production capacity by 275%, adding 7,000 kg of annual capacity and bringing the Company’s total production capacity to approximately 11,000 kg per year.

George Robinson, CEO of RavenQuest, stated “this is a very exciting time and inflection point for our organization. This milestone catapults our company toward dramatic cannabis production and revenue increases for 2019. We have been busy preparing for this pivotal moment. Our Edmonton team is ready and all equipment is in place, including our Orbital Garden 2.0 technology. Starting material has been carefully prepared and curated at our Markham facility and will be moved to Edmonton to begin production immediately” Robinson continued.

“Production will be ramped up rapidly and efficiently in order to meet supply agreements with our provincial partner, BCLDB, as well as major bulk buyer, Wayland Group” stated Robinson. “We have already pre-sold all cannabis production from our Markham and Edmonton facilities for the calendar year of 2019” he continued.

For more information, access RavenQuest’s investor presentation, fact sheet and videos here.

About RavenQuest BioMed Inc.

RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development. RavenQuest is a licensed producer with facilities located in Markham, Ontario and Edmonton, Alberta.

RavenQuest maintains a research partnership with McGill University focused upon cultivar (strain) recognition, plant stabilization and yield maximization of the cannabis plant. The Company focuses on partnerships with Indigenous communities.

On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.

I am more frustrated with Canada than RavenQuest.
Heath Canada, the Bureaucracy, in charge of implementing the licensing has failed miserably. It is as if Socialist don't care at all about the investment community as if money grows on trees. It takes initiative to make money which seems to be a foreign concept to them.

I think most investors have givin up on this crap stock